Welcome to our dedicated page for Regenxbio SEC filings (Ticker: RGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
REGENXBIO Inc. filings document governance, operating results and material events for a biotechnology company developing AAV gene therapies. Recent 8-K disclosures include quarterly and annual results, FDA communications involving RGX-121 and RGX-111, and regulatory updates tied to a Biologics License Application and investigational new drug applications.
The filing record also covers collaboration and license matters, including an amendment to the AbbVie collaboration for surabgene lomparvovec and a settlement related to the GSK-REGENXBIO sublicense. Proxy materials describe board elections, stockholder meeting matters, executive compensation, equity awards and other governance disclosures for the Delaware corporation.
REGENXBIO Inc. director Allan M. Fox reported new equity awards and updated indirect holdings. He received 9,807 shares of common stock as a time-based restricted stock unit grant, with all shares scheduled to vest on May 29, 2027, subject to continuous service.
He was also granted stock options for 46,600 shares at an exercise price of $7.01 per share, vesting on May 29, 2027 and expiring on May 29, 2036. Following these grants, he directly holds 28,861 common shares.
The filing also lists indirect holdings of common stock through entities including Quaker Gray LLC with 1,529,981 shares, HBF Gift Trust LLC with 315,000 shares, AMF Gift Trust LLC with 315,000 shares, and AMF Family Gift Trust LLC with 722,485 shares, with beneficial ownership of these indirect positions disclaimed except for his indirect pecuniary interest.
REGENXBIO Inc. director Jean Bennett received new equity awards as part of compensation. She was granted 9,807 shares of common stock in the form of a time-based restricted stock unit (RSU) award, bringing her total direct holdings to 28,861 common shares.
She was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share. Both the RSU and the option award are scheduled to vest on May 29, 2027, subject to her continuous service with REGENXBIO. The options expire on May 29, 2036.
REGENXBIO Inc. reported a sharp swing to a first quarter 2026 net loss while unveiling strong pivotal data for its Duchenne gene therapy RGX-202. Revenue fell to $6.4 million from $89.0 million a year earlier, mainly because prior-period Nippon Shinyaku license revenue and ZOLGENSMA royalties rolled off. The company posted a net loss of $90.1 million, or $1.72 per share, versus net income of $6.1 million last year.
Cash, cash equivalents and marketable securities were $150.5 million as of March 31, 2026, and management expects this to fund operations into early 2027. On the pipeline, the pivotal Phase III AFFINITY DUCHENNE trial met its primary endpoint, with 93% of RGX-202 patients achieving more than 10% microdystrophin expression and a statistically significant correlation with functional improvement, supporting plans to pursue accelerated approval and a potential 2027 commercial launch. The company also highlighted a lifted clinical hold on RGX-121 and expects a $100 million milestone from AbbVie when the first patient is dosed in the NAAVIGATE diabetic retinopathy study in Q2 2026.
REGENXBIO Inc. reported a sharp swing to a first quarter 2026 net loss while unveiling strong pivotal data for its Duchenne gene therapy RGX-202. Revenue fell to $6.4 million from $89.0 million a year earlier, mainly because prior-period Nippon Shinyaku license revenue and ZOLGENSMA royalties rolled off. The company posted a net loss of $90.1 million, or $1.72 per share, versus net income of $6.1 million last year.
Cash, cash equivalents and marketable securities were $150.5 million as of March 31, 2026, and management expects this to fund operations into early 2027. On the pipeline, the pivotal Phase III AFFINITY DUCHENNE trial met its primary endpoint, with 93% of RGX-202 patients achieving more than 10% microdystrophin expression and a statistically significant correlation with functional improvement, supporting plans to pursue accelerated approval and a potential 2027 commercial launch. The company also highlighted a lifted clinical hold on RGX-121 and expects a $100 million milestone from AbbVie when the first patient is dosed in the NAAVIGATE diabetic retinopathy study in Q2 2026.
REGENXBIO Inc. Chief Medical Officer Steve Pakola reported an open-market sale of 15,309 shares of common stock on May 11, 2026 at a weighted average price of $11.02 per share. The transaction was executed under a Rule 10b5-1 trading plan, and he continues to hold 232,617 shares directly.
State Street Corporation reported beneficial ownership of 2,731,553 shares of REGENXBIO Inc common stock, representing 5.3% of the class. The filing states shared voting power of 2,666,105 shares and shared dispositive power of 2,731,553 shares. The Schedule 13G names affiliated State Street entities as holders and is signed by a company officer.
Form 144 filing reports an insider sale under a 10b5-1 plan. The excerpt shows a 10b5-1 sale by Stephen Pakola reporting 5,124 shares sold on 03/10/2026 for $53,033.40. The filing lists 34,917 restricted stock units and notes restricted‑unit details dated 01/01/2026.
REGENXBIO Inc. (RGNX) is asking stockholders to vote at its May 29, 2026 annual meeting on six key items, including electing three Class II directors to serve until 2029 and ratifying PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
Stockholders will also cast a non-binding advisory vote on 2025 executive compensation and decide on two stock option exchange programs. One program would let non‑executive employees, and a separate one would let executive employees, voluntarily surrender underwater stock options for a smaller number of replacement options priced at current fair market value.
The proxy highlights REGENXBIO’s clinical progress in gene therapy, including ABBV‑RGX‑314 trials in eye diseases, RGX‑202 in Duchenne muscular dystrophy, and RGX‑121 for MPS II, as well as a $110.0 million upfront payment from a Nippon Shinyaku partnership and a royalty bond agreement of up to $250 million. The company reports ending 2025 with $240.9 million in cash, cash equivalents and marketable securities.
REGENXBIO Inc. is asking shareholders to vote at its May 29, 2026 Annual Meeting on director elections, ratification of PwC as auditor, an advisory "say-on-pay" vote, and two related stock option exchange proposals for non-executive and executive employees. The company highlights 2025 progress: completion of key trial enrollments 1,200 participants in ABBV-RGX-314 pivotal trials), a strategic partnership with Nippon Shinyaku with a $110.0 million upfront payment, and a $150.0 million royalty bond close with up to $250.0 million capacity. The company reported $240.9 million in cash, cash equivalents and marketable securities as of year-end 2025. The proxy also discloses regulatory setbacks: the FDA placed the RGX-121 program on clinical hold in January 2026 and issued a Complete Response Letter in February 2026; the company is developing responses to both actions.